Repository of Research and Investigative Information

Repository of Research and Investigative Information

Dezful University of Medical Sciences

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

(2021) Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. International Immunopharmacology. ISSN 15675769 (ISSN)

Full text not available from this repository.


Background: We examined the safety and efficacy of a treatment protocol containing Favipiravir for the treatment of SARS-CoV-2. Methods: We did a multicenter randomized open-labeled clinical trial on moderate to severe cases infections of SARS-CoV-2. Patients with typical ground glass appearance on chest computerized tomography scan (CT scan) and oxygen saturation (SpO2) of less than 93 were enrolled. They were randomly allocated into Favipiravir (1.6 gr loading, 1.8 gr daily) and Lopinavir/Ritonavir (800/200 mg daily) treatment regimens in addition to standard care. In-hospital mortality, ICU admission, intubation, time to clinical recovery, changes in daily SpO2 after 5 min discontinuation of supplemental oxygen, and length of hospital stay were quantified and compared in the two groups. Results: 380 patients were randomly allocated into Favipiravir (1 9 3) and Lopinavir/Ritonavir (1 8 7) groups in 13 centers. The number of deaths, intubations, and ICU admissions were not significantly different (26, 27, 31 and 21, 17, 25 respectively). Mean hospital stay was also not different (7.9 days SD = 6 in the Favipiravir and 8.1 SD = 6.5 days in Lopinavir/Ritonavir groups) (p = 0.61). Time to clinical recovery in the Favipiravir group was similar to Lopinavir/Ritonavir group (HR = 0.94, 95% CI 0.75 – 1.17) and likewise the changes in the daily SpO2 after discontinuation of supplemental oxygen (p = 0.46) Conclusion: Adding Favipiravir to the treatment protocol did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to clinical recovery and length of hospital stay. © 2021 Elsevier B.V.

Item Type: Article
Keywords: Clinical trial Covid19 Favipiravir Hydroxychloroquine Lopinavir Ritonavir SARS-CoV-2 angiotensin receptor antagonist anti-SARS-CoV-2 agent antibiotic agent anticoagulant agent creatinine dipeptidyl carboxypeptidase inhibitor famotidine hydroxymethylglutaryl coenzyme A reductase inhibitor immunoglobulin interferon lopinavir plus ritonavir nonsteroid antiinflammatory agent proton pump inhibitor remdesivir steroid abdominal pain adult anaphylaxis anemia anorexia antibiotic therapy antiviral therapy Article balance impairment blurred vision cardiomyopathy case control study combination drug therapy comparative effectiveness computer assisted tomography controlled study convalescence coronavirus disease 2019 coughing creatinine blood level data analysis software death diarrhea disease severity drug dose reduction drug efficacy drug safety dyspnea exploratory research fatigue female ground glass opacity hair loss headache heart arrhythmia hematuria hospital admission hospital mortality human hypothyroidism immunotherapy intensive care unit intention to treat analysis intervention study lacrimal gland disease length of stay lethargy loading drug dose major clinical study male median survival time middle aged mood disorder multicenter study nausea open study oxygen saturation oxygen therapy pain paresthesia pharyngitis plasmapheresis polyuria priority journal pruritus randomized controlled trial rash respiratory tract intubation Severe acute respiratory syndrome coronavirus 2 side effect single drug dose steroid therapy stupor thorax radiography treatment withdrawal urea nitrogen blood level vertigo vomiting xerostomia
Subjects: QW Microbiology and Immunology > QW 1-300 Microbiology
WF Respiratory System > WF 140-900 Diseases of the Respiratory System
Divisions: Education Vice-Chancellor Department > Faculty of Medicine > Departments of Clinical Sciences > Department of Infectious Diseases
Journal or Publication Title: International Immunopharmacology
Journal Index: Scopus
Volume: 95
Identification Number:
ISSN: 15675769 (ISSN)
Depositing User: مهندس مهدی شریفی

Actions (login required)

View Item View Item